Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Advertisement

Advertisement




Feb
20
Today In Oncology
Stage II Melanoma Adjuvant Pembrolizumab and Risk of New Skin Cancers
Long-Term Survival Results With Addition of Adjuvant mFOLFOX6 to Hepatectomy in Patients With Liver Metastases From Colorectal Cancer
Multidisciplinary Radiopharmaceutical Therapy Symposium: Highlights From the Inaugural New Meeting From ASTRO
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Genetics Pioneer Zsofia Stadler to Lead JCO Precision Oncology
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo